Grifols SA
(NASDAQ : GRFS)

( )
GRFS After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson -1.45%141.180.7%$2226.77m
PFEPfizer Inc. 2.25%35.380.9%$1423.63m
MRKMerck & Co., Inc. 1.05%82.480.7%$1317.79m
ABBVAbbVie, Inc. 1.48%79.732.3%$1252.38m
BMYBristol-Myers Squibb Co. 1.06%58.871.0%$1127.60m
LLYEli Lilly & Co. -0.33%145.741.1%$866.97m
AZNAstraZeneca Plc 1.82%44.651.2%$292.10m
NVSNovartis AG -0.89%84.860.2%$267.33m
GSKGlaxoSmithKline Plc 2.10%38.880.2%$250.76m
NVONovo Nordisk A/S 0.89%60.170.1%$178.16m
SNYSanofi 0.62%45.460.2%$169.22m
FTSVForty Seven, Inc. 0.05%95.510.0%$138.72m
BHCBausch Health Cos., Inc. 14.92%18.020.0%$122.30m
RGENRepligen Corp. 2.54%98.957.1%$68.30m
RETAReata Pharmaceuticals, Inc. 2.74%141.193.4%$64.19m

Company Profile

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.